2018-07-16T14:02:13-05:00 2017-08-31 KPMG LLP 550 S Hope St Suite 1500 Los Angeles CA 90071 990 2016-09-01 453682796 CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH % AMANDA ARELLANO CALI 8582421029 11119 N TORREY PINES RD STE 100 LA JOLLA CA 92037 KELLY SAN GEORGE CFO 8582421029 2018-07-13 true CAREY MCKEE P01281067 2139724000 2018-07-13 2016 2022-09-23 18:48:47Z PETER G SCHULTZ PHD 11119 N TORREY PINES RD 100 LA JOLLA CA 92037 35244708 false X WWW.CALIBR.ORG X 2011 CA THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (CALIBR) ACCELERATES THE TRANSLATION OF BASIC BIOMEDICAL RESEARCH TO NEW MEDICINES FOR UNMET MEDICAL NEEDS. 5 4 180 0 0 26498 49244 44005272 35162899 22453 25446 2837 7119 44057060 35244708 318540 314944 0 0 11983132 12959752 0 0 0 32768587 34364786 45070259 47639482 -1013199 -12394774 45727287 24003955 17795337 8466779 27931950 15537176 X OUR MISSION IS TO BUILD A UNIQUE INSTITUTE THAT BRIDGES BASIC RESEARCH AND DRUG DISCOVERY, AND THAT ATTRACTS THE BEST AND BRIGHTEST SCIENTISTS, PHYSICIANS AND STUDENTS TO WORK TOGETHER SYNERGISTICALLY TO FIND CURES FOR NEGLECTED HUMAN DISEASES. THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (CALIBR) IS A BIOMEDICAL RESEARCH ORGANIZATION LOCATED IN SAN DIEGO, CALIFORNIA. CALIBR BRIDGES THE GAP BETWEEN BASIC BIOMEDICAL RESEARCH AND THE CLINICAL APPLICATION OF RESEARCH DISCOVERIES TO HUMAN DISEASE. CALIBR COMMITS SUBSTANTIALLY ALL OF ITS RESOURCES TO BIOMEDICAL RESEARCH ACTIVITIES. CALIBR'S RESEARCH AND WORK WILL CATALYZE THE TRANSLATION OF DISCOVERIES BY SCIENTISTS AT OTHER SAN DIEGO RESEARCH INSTITUTES , AS WELL AS OTHER MAJOR RESEARCH INSTITUTES THROUGHOUT THE WORLD, INTO POTENTIAL NEW THERAPIES FOR MANY LIFE THREATENING AND DEBILITATING DISEASES. THESE DISEASES INCLUDE ORPHAN DISEASES, DEGENERATIVE DISEASES OF AGING, CANCER, AUTOIMMUNE DISEASES, AND INFECTIOUS DISEASES OF THE THIRD false false 42889979 314944 35162899 RESEARCH GRANTS AND CONTRACTS ARE RECEIVED FROM PUBLIC AND PRIVATE INSTITUTIONS AND ARE USED TO CONDUCT BIOMEDICAL RESEARCH. IN THE CURRENT FISCAL YEAR, CALIBR CONDUCTED RESEARCH THROUGH A PRIVATE COLLABORATION AGREEMENT ON AUTOIMMUNE AND INFLAMMATORY DISEASES, CANCER BIOLOGY, CARDIOVASCULAR METABOLIC DISEASES AND NEUROBIOLOGY. IN ADDITION, IT CONDUCTED RESEARCH FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY, JUVENILE DIABETES, AND TB DRUG DEVELOPMENT. 42889979 true true false false false false false false false false true false false false true true true false false false false false false false false false false true false true false false false false true false false false false false false false false false false false false true 48 0 true 180 true false false false false false false false false false false X 5 4 true false true false true true true true true false false true true true true true true false false false CA X AMANDA ARELLANO 8582421029 11119 N TORREY PINES RD STE 100 LA JOLLA CA 92037 X Peter G Schultz CEO & Board Member 20.0 0.0 X X 502433 0 0 Herbert Boyer Board Member (AS OF 11/28/16) 1.0 0.0 X 0 0 0 Mark Edwards Board Member 1.0 0.0 X 0 0 0 Isy Goldwasser Board Member 1.0 0.0 X 0 0 0 Richard King AS OF 112816 Board Member (THRU 04/01/17) 1.0 0.0 X 0 0 0 Christopher T Walsh Board Member 1.0 0.0 X 0 0 0 Matthew Tremblay COO/Secretary 20.0 0.0 X 252359 0 7570 Sabrina Johnson CFO/Treasurer (Thru 07/31/17) 20.0 0.0 X 143279 0 23560 Kelly San George CFO/TREASURER (AS OF 08/21/17) 40.0 0.0 X 0 0 0 Arnab Chatterjee VP Medicinal Chemistry 40.0 0.0 X 226849 0 5280 Tim Wright EVP Trans Sci (THRU 9/30/16) 40.0 0.0 X 380425 0 9258 Vadim Klyushnichenko VP Pharmaceutical Sciences 40.0 0.0 X 241495 0 9804 Jing Li VP Program Management 40.0 0.0 X 199836 0 5108 Hank MJ Petrassi Director Medicinal Chemistry 40.0 0.0 X 199464 0 19038 2146140 0 79618 27 false true false Wilson Sonsini Goodrich Rosati PO Box 742866 Los Angeles CA 900742866 Legal Services 1069398 Cooley LLP 101 California St San Francisco CA 941115800 Legal Services 845428 RSM US LLP 331 West 3rd Street Davenport IA 52801 Accounting/Audit 162730 Ingenium LLC 2280 Micro Place Escondido CA 92029 Waste Removal 139151 Meso Scale Discovery LLC 1601 Research Blvd Rockville MD 20850 Lab Supplies & Equip 111206 5 49244 49244 Medical Research 541700 35162899 35162899 35162899 25446 25446 0 0 5651 5651 0 5651 5651 0 0 0 0 0 0 0 0 0 0 OTHER INCOME 1468 1468 1468 35244708 35162899 32565 314944 314944 0 0 0 917491 917491 0 10033247 9196208 837039 185711 175848 9863 1010975 890885 120090 812328 694779 117549 1051248 783457 267791 660083 373472 286611 178022 178022 0 0 0 0 0 171113 63804 107309 1147471 455594 691877 0 3774542 3057139 717403 177243 164178 13065 0 40925 40710 215 0 0 1760036 1740582 19454 109910 109910 Lab Supplies 6712979 6712979 Outsourced Research Services 17005223 16977486 27737 Service Agreements 829024 797916 31108 Recruiting Expenses 261607 161510 100097 485360 288488 196872 47639482 42889979 4749503 0 300 300 35057746 11711232 2031619 2367026 0 0 0 0 0 0 0 0 0 0 487619 1236673 12072906 6437623 6255966 5635283 6470 0 0 416891 0 0 1845180 2594163 42387 42387 45727287 24003955 3219466 2972585 0 0 13835572 4609279 0 0 0 0 0 0 0 0 0 0 740299 884915 17795337 8466779 X 27931950 15537176 0 0 0 0 27931950 15537176 45727287 24003955 -12394774 X false true X true true true X UC San Diego Medical Center San Diego CA Scripps Memorial Hospital La Jolla La Jolla CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 305553 171592 133961 11718749 6233608 5485141 48604 32423 16181 5635283 0 DEFERRED RENT 884915 884915 X 35239057 35239057 5651 5651 35244708 47633831 47633831 5651 5651 47639482 LIABILITY FOR UNCERTAIN TAX POSITIONS (ASC 740) FORM 990, SCHEDULE D, PART X, LINE 2 THE INSTITUTE ADOPTED ACCOUNTING GUIDANCE RELATING TO ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES, WHICH IS PRIMARILY CODIFIED IN FINANCIAL ACCOUNTING STANDARDS BOARD (FASB) ACCOUNTING STANDARDS CODIFICATION 740. THE INSTITUTE FILES A FORM 990 (RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX) ANNUALLY. WHEN THESE RETURNS ARE FILED, IT IS HIGHLY CERTAIN THAT SOME POSITIONS TAKEN WOULD BE SUSTAINED UPON EXAMINATION BY THE TAXING AUTHORITIES, WHILE OTHERS ARE SUBJECT TO UNCERTAINTY ABOUT THE MERITS OF THE TAX POSITION TAKEN OR THE AMOUNT OF THE POSITION THAT WOULD ULTIMATELY BE SUSTAINED. EXAMPLES OF TAX POSITIONS COMMON TO THE INSTITUTE INCLUDE SUCH MATTERS AS THE TAX-EXEMPT STATUS OF THE ENTITY AND VARIOUS POSITIONS RELATIVE TO POTENTIAL SOURCES OF UBI. UBI IS REPORTED ON FORM 990-T, AS APPROPRIATE. THE BENEFIT OF TAX POSITION IS RECOGNIZED IN THE FINANCIAL STATEMENTS IN THE PERIOD DURING WHICH, BASED ON ALL AVAILABLE EVIDENCE, MANAGEMENT BELIEVES IT IS MORE LIKELY THAN NOT THAT THE POSITION WILL BE SUSTAINED UPON EXAMINATION, INCLUDING THE RESOLUTION OF APPEALS OR LITIGATION PROCESSES, IF ANY. TAX POSITIONS ARE NOT OFFSET OR AGGREGATED WITH OTHER POSITIONS. TAX POSITIONS THAT MEET THE MORE-LIKELY-THAN-NOT RECOGNITION THRESHOLD ARE MEASURED AS THE LARGEST AMOUNT OF TAX BENEFIT THAT IS MORE THAN 50 PERCENT LIKELY TO BE REALIZED ON SETTLEMENT WITH THE APPLICABLE TAXING AUTHORITY. THE PORTION OF THE BENEFITS ASSOCIATED WITH TAX POSITIONS TAKEN THAT EXCEEDS THE AMOUNT MEASURED AS DESCRIBED ABOVE IS REFLECTED AS A LIABILITY FOR UNRECOGNIZED TAX BENEFITS IN THE ACCOMPANYING STATEMENTS OF FINANCIAL POSITION, ALONG WITH ANY ASSOCIATED INTEREST AND PENALTIES THAT WOULD BE PAYABLE TO THE TAXING AUTHORITIES UPON EXAMINATION. AS OF AUGUST 31, 2017 AND 2016, THE INSTITUTE HAS ADDRESSED UNCERTAINTY IN ITS INCOME TAX POSITION UNDER THE GUIDANCE, AND THERE ARE NO UNRECOGNIZED/DERECOGNIZED TAX BENEFITS REQUIRING AN ACCRUAL. FORMS 990 AND 990-T FILED BY THE INSTITUTE ARE SUBJECT TO EXAMINATION BY THE INTERNAL REVENUE SERVICE UP TO THREE YEARS FROM THE EXTENDED DUE DATE OF EACH RETURN. MANAGEMENT BELIEVES FORMS 990 AND 990-T HAVE BEEN FILED APPROPRIATELY. REVENUE ON FORM 990, NOT ON AUDITED FINANCIALS SCHEDULE D, PART XI, LINE 4B RENTAL INCOME, REPORTED NET IN AUDITED FINANCIALS $5,651 EXPENSES ON FORM 990, NOT ON AUDITED FINANCIALS SCHEDULE D, PART XII, LINE 4B RENTAL EXPENSES, REPORTED NET IN AUDITED FINANCIALS $5,651 true THE SCRIPPS RESEARCH INSTITUTE 10550 N TORREY PINES RD TPC-7 LA JOLLA CA 92037 330435954 501(c)(3) 314944 N/A N/A SUPPORT FOR POSTDOCTORAL FELLOWS 1 GRANT MONITORING SCHEDULE I, PART 1, LINE 2 FUNDING WAS PROVIDED TO THE SCRIPPS RESEARCH INSTITUTE TO SUPPORT A NUMBER OF POSTDOCTORAL FELLOWSHIPS FOR RESEARCH AND LAB SUPPORT ACTIVITIES. SINCE THESE FELLOWS ARE WORKING AT ONE OF THE HOSPITALS OPERATING IN CONJUNCTION WITH THE INSTITUTE, THERE IS CONTINUOUS MONITORING OF THE USE OF THE SUPPORT PROVIDED. X X X false false false false false false false false false Peter G Schultz CEO & Board Member 302433 0 200000 0 0 0 0 0 0 0 502433 0 0 0 Matthew Tremblay COO/Secretary 195359 0 57000 0 0 0 7570 0 0 0 259929 0 0 0 Sabrina Johnson CFO/Treasurer (Thru 07/31/17) 126612 0 16667 0 0 0 4142 0 19418 0 166839 0 0 0 Arnab Chatterjee VP Medicinal Chemistry 175849 0 51000 0 0 0 5280 0 0 0 232129 0 0 0 Tim Wright EVP Trans Sci (THRU 9/30/16) 270425 0 110000 0 0 0 0 0 9258 0 389683 0 0 0 Vadim Klyushnichenko VP Pharmaceutical Sciences 179495 0 62000 0 0 0 4926 0 4878 0 251299 0 0 0 Jing Li VP Program Management 167836 0 32000 0 0 0 5108 0 0 0 204944 0 0 0 Hank MJ Petrassi Director Medicinal Chemistry 154464 0 45000 0 0 0 4462 0 14576 0 218502 0 0 0 Peter G Schultz CEO & Board Member 314944 Fellowships SCRIPPS RSRCH INST FELLOW BUSINESS RELATIONSHIP FORM 990, PART VI, LINE 2 CEO AND BOARD CHAIR PETER SCHULTZ SERVES ON A NUMBER OF OTHER CORPORATE BOARDS WITH BOARD MEMBER ISY GOLDWASSER. CHANGES TO THE ORGANIZATION'S GOVERNING DOCUMENTS FORM 990, PART VI, LINE 4 THE INSTITUTES ARTICLES AND BYLAWS WERE AMENDED ON SEPTEMBER 30, 2016. THE SIGNIFICANT CHANGES ARE FOR THE ADDITION OF A SOLE CORPORATE MEMBER AND THE EXPANSION OF THE NUMBER OF BOARD OF DIRECTORS. THE NUMBER OF DIRECTORS AUTHORIZED WAS EXPANDED FROM FIVE TO SIX. ONE DIRECTOR IS DESIGNATED BY THE MEMBER, ANOTHER DIRECTOR IS THE CEO OF THE INSTITUTE AS AN EX OFFICIO DIRECTOR, AND THE REMAINING FOUR DIRECTORS ARE DESIGNATED BY THE MAJORITY VOTE OF THE INSTITUTES BOARD OF DIRECTORS. MEMBERS/STOCKHOLDERS OF ORGANIZATION FORM 990, PART VI, SECTION A, LINE 6 THE SCRIPPS RESEARCH INSTITUTE, IS THE SOLE MEMBER OF THE INSTITUTE. ELECTION POWERS FORM 900, PART VI, SECTION A, LINE 7A THE SOLE MEMBER HAS THE POWER TO DESIGNATE ONE OF THE SIX DIRECTORS. AFTER OCTOBER 1, 2021 (OR EARLIER DATE IF AGREED UPON BY THE INSTITUTE), THE MEMBER SHALL HAVE THE POWER TO DESIGNATE ALL DIRECTORS OF THE INSTITUTE. ORGANIZATIONAL GOVERNANCE DECISIONS FORM 900, PART VI, SECTION A, LINE 7B THE MEMBERS POWERS INCLUDE THE ABILITY TO SELL, LEASE, EXCHANGE OR DISPOSE OF ALL OR SUBSTANTIALLY ALL OF THE PROPERTY OF THE INSTITUTE; DETERMINATIONS AS TO SUBSTANTIALLY RELATED TO EXEMPT PURPOSE FOR LICENSING OR OTHER TRANSFER OF INTELLECTUAL PROPERTY OF THE INSTITUTE; FIXING THE COMPENSATION OF THE INSTITUTES DIRECTORS; AND AMENDMENTS TO THE INSTITUTES ARTICLES AND/OR BYLAWS. THE INSTITUTE RETAINS THE RIGHT TO TERMINATE THE POWERS OF THE SOLE MEMBER. FORM 990 REVIEW PROCESS FORM 990, PART VI, LINE 11B INFORMATION USED TO PREPARE THE FORM 990 WAS COMPILED BY CALIBR'S PERSONNEL. THE RETURN WAS PREPARED WITH THE ASSISTANCE OF ITS PUBLIC ACCOUNTING FIRM. THE FORM 990 WAS REVIEWED BY CALIBR'S AUDIT COMMITTEE, WHICH HAS AUTHORITY AND OVERSIGHT OF CALIBR'S AUDIT AND TAX PREPARATION. A COMPLETE COPY OF THE FORM 990 WAS PROVIDED TO THE FULL BOARD AFTER REVIEW BY THE AUDIT COMMITTEE AND PRIOR TO FILING WITH THE IRS. CONFLICT OF INTEREST POLICY FORM 990, PART VI, LINE 12C ON AN ANNUAL BASIS, CALIBR DISTRIBUTES CONFLICT OF INTEREST QUESTIONNAIRES WHICH THE BOARD MEMBERS, OFFICERS, AND KEY EMPLOYEES COMPLETE AND RETURN. THE CEO AND VP OF FINANCE AND OPERATIONS REVIEW THE RETURNED FORMS FOR COMPLIANCE. IF A CONFLICT IS DISCOVERED IT IS ESCALATED TO THE APPROPRIATE PARTY WITHIN CALIBR AND THE PERSON RECUSES HIMSELF OR HERSELF FROM THE GOVERNING BODY'S DELIBERATIONS AND DECISIONS IN THE TRANSACTION, AND THE MEETING MINUTES REFLECT THAT THE PARTY IN QUESTION RECUSED THEMSELVES. IN THE EVENT A CONFLICT ARISES THE INDEPENDENT BOARD MEMBERS DISCUSS THE TRANSACTION, THE ALTERNATIVES, AND EVALUATE WHAT IS BEST FOR THE ORGANIZATION. MEETING MINUTES REFLECT THE DISCUSSIONS AND DECISION, INCLUDING WHO VOTED AND WHO WAS RECUSED FROM DISCUSSION AND VOTING. BOARD MEMBERS ARE REQUIRED TO BRING FORTH ANY NEW CONFLICTS OF INTEREST AS THEY ARISE. COMPENSATION OF THE CEO FORM 990, PART VI, LINE 15A THE BOARD OF DIRECTORS APPOINTS A SPECIAL COMMITTEE, COMPRISED SOLELY OF INDEPENDENT NON-EMPLOYEE DIRECTORS, NONE OF WHICH HAVE A CONFLICT OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENT, TO BE ACCOUNTABLE FOR SETTING THE CEOS COMPENSATION PACKAGE. THE BOARD ENSURES THAT COMPENSATION OF THE INSTITUTE CEO SHALL BE REVIEWED NO LESS THAN ONCE IN THREE YEARS. CALIBR'S CEO IS ELIGIBLE FOR A BASE SALARY FOR PERFORMANCE OF SERVICES IN ANY GIVEN ONE YEAR PERIOD AND SHALL AUTOMATICALLY BE DUE THE BOARD'S PREDETERMINED AND CONTEMPORANEOUSLY APPROVED FAIR AND REASONABLE BASE SALARY, SUBJECT TO A CAP OF $1.05 MILLION PER YEAR. ADDITIONALLY, THE CEO IS ELIGIBLE TO RECEIVE BONUS INCENTIVE PAY SEPARATE FROM COMPENSATION PAYMENTS IN AMOUNTS DETERMINED BY THE BOARD AT ITS SOLE REASONABLE DISCRETION, PROVIDED THAT SUCH BONUS SHALL NOT CAUSE THE TOTAL COMPENSATION OF CEO TO EXCEED THE CAP. AT CEO'S SOLE DISCRETION, THE CEO MAY WAIVE THE RIGHT TO RECEIVE ALL OR PART OF THE PAYMENTS DUE BEFORE RECEIPT, PROVIDED THAT THE CEO GIVES WRITTEN NOTICE TO INSTITUTE OF THE AMOUNT OF PAYMENT(S) WAIVED. IT IS EXPRESSLY UNDERSTOOD BY CALIBR AND CEO THAT WAIVER OF PAYMENT(S) SHALL IN NO WAY ALTER OR INFLUENCE INSTITUTE'S FUTURE PAYMENT OBLIGATIONS TO THE CEO OR THE DETERMINATION OR IMPLEMENTATION OF THE COMPENSATION CAP. EFFECTIVE OCTOBER 1, 2016 THE CEO HAS A COMPENSATION ARRANGEMENT THAT INCLUDES $502,433 IN BASE COMPENSATION, BONUSES AND NON-MONETARY BENEFITS, AND PREREQUISITES FOR THE FISCAL YEAR ENDING AUGUST 31, 2017. KEY DELIBERATIONS OF THE COMMITTEE ARE CONTEMPORANEOUSLY DOCUMENTED IN MINUTES WHICH ARE APPROVED AT THE NEXT COMMITTEE MEETING. THE DOCUMENTATION INCLUDES THE TERMS OF THE DELIBERATIONS, THOSE THAT VOTED ON IT, AND A DESCRIPTION OF PUBLICALLY AVAILABLE COMPENSATION DATA RELIED UPON AND HOW IT WAS OBTAINED. OTHER OFFICER COMPENSATION FORM 990, PART VI, LINE 15B OTHER OFFICER SALARIES ARE DETERMINED BY CALIBR'S CEO BASED ON COMPARABLE SALARIES FOR INDIVIDUALS HAVING SIMILAR ROLES AND RESPONSIBILITIES AT SIMILAR NON-PROFITS AND BIOTECH COMPANIES. PUBLIC AVAILABILITY OF DOCUMENTATION FORM 990, PART VI, LINE 19 GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST.